OM-85 reduces SARS-COV-2 viral RNA expression in nasopharyngeal cells from COVID-19 patients
G. Cassao, K. H. Antunes, J. I. B. Goncalves, L. D. Santos, B. L. Abbadi, C. V. Bizarro, P. Machado, L. A. Basso, C. Pasquali, R. Stein, A. P. D. d. Souza
Abstract
OM-85 is a bacterial lysate from common respiratory tract pathogens, with an excellent safety profile, widely used to prevent recurrent respiratory tract infections. Several studies have been reporting the antiviral roles of OM-85. Here we demonstrated the effect of ex-vivo OM-85 exposure in nasopharyngeal cells collected from COVID-19 patients. OM-85 decreased the SARS-CoV-2 N1 gene expression and increased RIG-I (DDX58) gene expression in these cells. These data support the antiviral effect of OM-85 against SARS-CoV-2.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The SARS-CoV-2 cellular receptor ACE2 is expressed in oropharyngeal cells and is modulated in vitro by the bacterial lysate Lantigen B
C. Pizzimenti, A. D'Agostino, … G. Melioli·bioRxiv·May 6, 2022
- Mutations in SARS-CoV-2 Nsp1 are critical determinants of viral pathogenicity in mice
Nathaniel D. Jackson, Fuchun Zhou, … Luis Martínez‐Sobrido·bioRxiv·Aug 19, 2026
- A traditional medicine, Respiratory Detox Shot (RDS), inhibits the infection of SARS-CoV, SARS-CoV-2, and the Influenza A virus in vitro
B. Hetrick, D. Yu, … Y. Wu·bioRxiv·Dec 10, 2020
- Low expression of EXOSC2 protects against clinical COVID-19 and impedes SARS-CoV-2 replication
Tobias Moll, Valerie Odon, … Johnathan Cooper‐Knock·Life Science AlliancePeer-reviewed·Oct 14, 2022
- An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus
T. P. Sheahan, A. C. Sims, … R. S. Baric·bioRxiv·Mar 19, 2020
- Nasally-delivered interferon-{lambda} protects mice against upper and lower respiratory tract infection of SARS-CoV-2 variants including Omicron
Z. Chong, C. E. Karl, … M. S. Diamond·bioRxiv·Jan 21, 2022